ArriVent Q2 2026: $93.2M H1 Loss, Patent Reexamination, and $140M ATM Raise
AVBP sits 95% above its 52-week low of $16.1.
Summary
ArriVent BioPharma reported a $93.2M net loss for H1 2026, disclosed a USPTO reexamination of a core firmonertinib patent, and raised $140M via ATM sales. Cash runway extends at least 12 months.
Key Events · Earnings and Guidance · AVBP
-
USPTO Reexamines Firmonertinib Patent
The USPTO granted an ex parte reexamination of U.S. Reissue Patent No. 48,687, which covers firmonertinib. An anonymous third party alleges the claims are obvious. ArriVent says it will vigorously defend the patent.
-
ATM Program Raised $140M
During H1 2026, ArriVent sold 5,358,318 shares under its at-the-market program for net proceeds of $140.0 million. Approximately $229.1 million remains available for future sales.
-
Cash Runway of 12+ Months
Cash, cash equivalents, and short-term investments totaled $373.1 million as of June 30, 2026, which management states is sufficient to fund operations for at least twelve months.
-
Lepu Milestone Payment
Lepu earned $12.0 million in developmental milestone payments during H1 2026, of which $6.0 million had been paid as of June 30, 2026.
Analysis · AVBP · Life Sciences
ArriVent's 10-Q confirms the Q2 loss already reported, but adds two material items: the USPTO granted an ex parte reexamination of a key firmonertinib patent, and the company raised $140 million through its ATM program during the first half. The patent challenge is a direct threat to the lead asset's IP protection, while the ATM sales show ongoing dilution. Cash of $373.1 million provides at least a 12-month runway, but the patent risk and continued equity issuance are the key investor concerns.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVBP was trading at $31.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $16.10 to $35.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.